Lianne B Dolan1,2, Kristin Campbell3, Karen Gelmon4, Sarah Neil-Sztramko5, Daniel Holmes6, Donald C McKenzie7,8. 1. School of Kinesiology, University of British Columbia, Vancouver, BC, Canada. lbdolan@alumni.ubc.ca. 2. Allan McGavin Sports Medicine Clinic, 3055 Wesbrook Mall, Vancouver, BC, Canada. lbdolan@alumni.ubc.ca. 3. Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada. 4. Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. 5. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. 6. Department of Pathology and Laboratory Medicine, St. Paul's Hospital Vancouver British Columbia, Vancouver, Canada. 7. School of Kinesiology, University of British Columbia, Vancouver, BC, Canada. 8. Division of Sports Medicine, University of British Columbia, Vancouver, BC, Canada.
Abstract
BACKGROUND:Exercise therapy is being explored in a variety of cancer populations to counteract treatment-related deconditioning. Higher intensity interval protocols are being prescribed to improve physical function and attenuate surrogates of comorbidity in non-cancer populations. The purpose of this study is to explore the safety of higher intensity exercise stimuli on cardiorespiratory fitness (VO2peak) in breast cancer survivors. METHODS:Postmenopausal breast cancer survivors were randomized into three groups: supervised aerobic interval training (AIT), supervised continuous moderate exercise training (CMT), and an unsupervised control group (CON). For 6 weeks, AIT exercised between 70 and 100% VO2peak, while CMT exercised between 60 and 70% VO2peak. Both groups followed a matched-work design. RESULTS:Thirty-three participants completed the study (age, 57.2 (9) years; weight, 67.6 (12) kg) with no adverse advents. Between-group baseline values were non-significant. VO2peak at baseline (25.3 (5.4) mL·kg(-1)·min(-1)) was below population norms. Compared to CON, cardiorespiratory fitness improved in AIT and CMT by 12% (P < 0.001) with no significant difference between exercise groups. AIT had a greater influence on lower extremity strength (P = 0.026) and body weight (P = 0.031). CONCLUSION: This pilot study provides evidence that similar to CMT, AIT can safely increase VO2peak in a small group of breast cancer survivors. Further exploration of the benefits of implementing higher intensity training protocols is warranted.
RCT Entities:
BACKGROUND: Exercise therapy is being explored in a variety of cancer populations to counteract treatment-related deconditioning. Higher intensity interval protocols are being prescribed to improve physical function and attenuate surrogates of comorbidity in non-cancer populations. The purpose of this study is to explore the safety of higher intensity exercise stimuli on cardiorespiratory fitness (VO2peak) in breast cancer survivors. METHODS: Postmenopausal breast cancer survivors were randomized into three groups: supervised aerobic interval training (AIT), supervised continuous moderate exercise training (CMT), and an unsupervised control group (CON). For 6 weeks, AIT exercised between 70 and 100% VO2peak, while CMT exercised between 60 and 70% VO2peak. Both groups followed a matched-work design. RESULTS: Thirty-three participants completed the study (age, 57.2 (9) years; weight, 67.6 (12) kg) with no adverse advents. Between-group baseline values were non-significant. VO2peak at baseline (25.3 (5.4) mL·kg(-1)·min(-1)) was below population norms. Compared to CON, cardiorespiratory fitness improved in AIT and CMT by 12% (P < 0.001) with no significant difference between exercise groups. AIT had a greater influence on lower extremity strength (P = 0.026) and body weight (P = 0.031). CONCLUSION: This pilot study provides evidence that similar to CMT, AIT can safely increase VO2peak in a small group of breast cancer survivors. Further exploration of the benefits of implementing higher intensity training protocols is warranted.
Authors: K Meyer; L Samek; M Schwaibold; S Westbrook; R Hajric; M Lehmann; D Essfeld; H Roskamm Journal: Eur Heart J Date: 1996-07 Impact factor: 29.983
Authors: Martha Gulati; Dilip K Pandey; Morton F Arnsdorf; Diane S Lauderdale; Ronald A Thisted; Roxanne H Wicklund; Arfan J Al-Hani; Henry R Black Journal: Circulation Date: 2003-09-15 Impact factor: 29.690
Authors: Hendrik Mugele; Nils Freitag; Jannik Wilhelmi; Yanxiang Yang; Sulin Cheng; Wilhelm Bloch; Moritz Schumann Journal: J Cancer Surviv Date: 2019-02-26 Impact factor: 4.442
Authors: Maxime Caru; François Lalonde; Elise Legault; Daniel Curnier; David H St-Pierre; Alain Steve Comtois; François Tournoux Journal: Am J Cancer Res Date: 2019-12-01 Impact factor: 6.166
Authors: Sara Mijwel; Malin Backman; Kate A Bolam; Anna Jervaeus; Carl Johan Sundberg; Sara Margolin; Maria Browall; Helene Rundqvist; Yvonne Wengström Journal: Breast Cancer Res Treat Date: 2017-11-14 Impact factor: 4.872
Authors: Rebecca R Turner; Liz Steed; Helen Quirk; Rosa U Greasley; John M Saxton; Stephanie Jc Taylor; Derek J Rosario; Mohamed A Thaha; Liam Bourke Journal: Cochrane Database Syst Rev Date: 2018-09-19